Literature DB >> 19689543

Primary cutaneous aspergillosis in an immunocompetent patient: successful treatment with oral voriconazole.

Brittany Craiglow1, Ginette Hinds, Richard Antaya, Michael Girardi.   

Abstract

We report a case of primary cutaneous aspergillosis in an immunocompetent child that responded rapidly to oral voriconazole therapy. Voriconazole may be considered as a treatment option for pediatric patients with primary cutaneous aspergillosis.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19689543     DOI： 10.1111/j.1525-1470.2009.00971.x

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN： 0736-8046            Impact factor:   1.588


  4 in total

Review 1.  Antifungal therapy in children: an update.

Authors:  Valerio Cecinati; Chiara Guastadisegni; Fabio Giovanni Russo; Letizia Pomponia Brescia
Journal:  Eur J Pediatr       Date:  2012-06-01       Impact factor: 3.183

2.  Cutaneous aspergillosis masquerading in sporotrichoid morphology in an immunocompetent host.

Authors:  Vikas Pathania; Sunmeet Sandhu; P Sengupta; Kanwaljit Kaur
Journal:  Med J Armed Forces India       Date:  2020-12-31

3.  Antifungal agents in current pediatric practice.

Authors:  Cecinati Valerio; Teresa Perillo; Letizia Brescia; Fabio Giovanni Russo
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

Review 4.  Factors affecting patient outcome in primary cutaneous aspergillosis.

Authors:  Alexander M Tatara; Antonios G Mikos; Dimitrios P Kontoyiannis
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.